<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50131">Decitabine</z:chebi> is a hypomethylating agent with activity in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>It is largely unknown whether treatment with this drug before allo-SCT will increase the toxicity of the preparative regimen or otherwise affect the results of the transplant </plain></SENT>
<SENT sid="2" pm="."><plain>We report the outcome of 17 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with a median age of 55.5 years (range, 36-66 years) who underwent an allo-SCT (12 siblings, 5 unrelated) after prior therapy with <z:chebi fb="0" ids="50131">decitabine</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Preparative regimens consisted of fludarabine in combination with BU (n=8) or melphalan (n=9) </plain></SENT>
<SENT sid="4" pm="."><plain>The source of stem cells was marrow in four patients and peripheral blood (PB) in 13 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Thirteen patients were in CR within 100 days of transplant </plain></SENT>
<SENT sid="6" pm="."><plain>With a median follow-up of 12 months (range, 3-35 months), 11 patients are alive; eight in CR and three with progressive disease </plain></SENT>
<SENT sid="7" pm="."><plain>Prior therapy with hypomethylating agents did not increase toxicity and may improve the outcome of allogeneic transplant in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and should be evaluated in a prospective trial </plain></SENT>
</text></document>